• Alias: BIBW2992
    • Orally bioavailable EGFR and HER2 inhibitor
    • FDA approved on June 12, 2013, for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test
    • Currently in phase 2 trials for breast cancer with overexpression of HER2 growth receptor
    • Recommended dose: 40 mg once daily. May be taken 1 hour before or 2 hours after meals
    • Half-life: 34 hours
    • Metabolism: BCRP and P-glycoprotein substrate
    • Common side effects: Diarrhea, acne/rash/pruritus, stomatitis, paronychia, dry skin, decreased appetite
    Other topics in Targeted and Immunotherapy Agents